Adaptive Biotechnologies, Genentech announce FDA acceptance of investigational new drug application

By The Science Advisory Board staff writers

May 9, 2023 -- Adaptive Biotechnologies on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application submitted by its collaborator, Genentech, for a neoantigen-directed T-cell receptor (TCR)-based T-cell therapy.

This IND is the first TCR-based therapy drug candidate to advance to clinical development from Adaptive Biotechnologies' oncology collaboration with Genentech, a member of the Roche Group.

Under the terms of the collaboration agreement signed in 2019, Genentech has responsibility for clinical, regulatory, and commercialization efforts for any T-cell therapy product candidate.

The collaboration utilizes Genentech's cancer immunotherapy research and development expertise and Adaptive's proprietary T-cell receptor (TCR) discovery platform, with the aim of developing tailored cellular therapy for each patient's individual cancer, the firms said.

Copyright © 2023

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.